Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit for more info.

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Direct download: GRACEcast-339_ASCO_2015_RET_Lung_Cancer_Next_Big_Target.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT